{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:42:35Z","timestamp":1787510555820,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s11239-021-02628-8","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T22:02:33Z","timestamp":1641247353000},"page":"671-682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients"],"prefix":"10.1007","volume":"53","author":[{"given":"Bryan","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Sze Jen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyneth","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith Ruo En","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Han","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Yi Vanessa","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Xuan","family":"Quek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yip Han","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew-Pang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huay-Cheem","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0640-0430","authenticated-orcid":false,"given":"Nicholas W. S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poay Huan","family":"Loh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"3","key":"2628_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMra1210816","volume":"368","author":"GG Stefanini","year":"2013","unstructured":"Stefanini GG, Holmes DR (2013) Drug-eluting coronary-artery stents. N Engl J Med 368(3):254\u2013265","journal-title":"N Engl J Med"},{"issue":"9","key":"2628_CR2","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.058560","volume":"125","author":"L R\u00e4ber","year":"2012","unstructured":"R\u00e4ber L, Magro M, Stefanini GG et al (2012) Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents. Circulation 125(9):1110\u20131121","journal-title":"Circulation"},{"issue":"3","key":"2628_CR3","first-page":"332","volume":"5","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Windecker S (2012) Stent thrombosis. Circulation 5(3):332\u2013335","journal-title":"Circulation"},{"issue":"7","key":"2628_CR4","first-page":"330","volume":"25","author":"H Dores","year":"2013","unstructured":"Dores H, Raposo L, Campante Teles R et al (2013) Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry. J Invasive Cardiol 25(7):330\u2013336","journal-title":"J Invasive Cardiol"},{"issue":"6","key":"2628_CR5","first-page":"626","volume":"5","author":"SS Naidu","year":"2012","unstructured":"Naidu SS, Krucoff MW, Rutledge DR et al (2012) Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC: Cardiovasc Interv 5(6):626\u2013635","journal-title":"JACC: Cardiovasc Interv"},{"issue":"11","key":"2628_CR6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","volume":"57","author":"G Nakazawa","year":"2011","unstructured":"Nakazawa G, Otsuka F, Nakano M et al (2011) The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. J Am Coll Cardiol 57(11):1314\u20131322","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2628_CR7","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2011.10.909","volume":"59","author":"S-J Park","year":"2012","unstructured":"Park S-J, Kang S-J, Virmani R, Nakano M, Ueda Y (2012) In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 59(23):2051\u20132057","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2628_CR8","first-page":"300","volume":"2","author":"V Finn Aloke","year":"2009","unstructured":"Finn Aloke V, Nakazawa G, Kolodgie Frank D, Virmani R (2009) Temporal course of neointimal formation after drug-eluting stent placement. JACC: Cardiovasc Interv 2(4):300\u2013302","journal-title":"JACC: Cardiovasc Interv"},{"issue":"1","key":"2628_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jacc.2005.07.071","volume":"47","author":"JR Nebeker","year":"2006","unstructured":"Nebeker JR, Virmani R, Bennett CL et al (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47(1):175\u2013181","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2628_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner M, Finn AV, Farb A et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1):193\u2013202","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2628_CR11","first-page":"300","volume":"2","author":"AV Finn","year":"2009","unstructured":"Finn AV, Nakazawa G, Kolodgie FD, Virmani R (2009) temporal course of neointimal formation after drug-eluting stent placement. JACC: Cardiovasc Interv 2(4):300\u2013302","journal-title":"JACC: Cardiovasc Interv"},{"issue":"Suppl F","key":"2628_CR12","doi-asserted-by":"publisher","first-page":"F28","DOI":"10.4244\/EIJV5IFA5","volume":"5","author":"M Vorpahl","year":"2009","unstructured":"Vorpahl M, Finn AV, Nakano M, Virmani R (2009) The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention 5(Suppl F):F28-35","journal-title":"EuroIntervention"},{"issue":"5","key":"2628_CR13","first-page":"462","volume":"10","author":"G El-Hayek","year":"2017","unstructured":"El-Hayek G, Bangalore S, Casso Dominguez A et al (2017) Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC: Cardiovasc Interv 10(5):462\u2013473","journal-title":"JACC: Cardiovasc Interv"},{"issue":"10","key":"2628_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 68(10):1082\u20131115","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2628_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39(3):213\u2013260","journal-title":"Eur Heart J"},{"issue":"15","key":"2628_CR16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.120.046308","volume":"142","author":"SU Khan","year":"2020","unstructured":"Khan SU, Singh M, Valavoor S et al (2020) dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents. Circulation 142(15):1425\u20131436","journal-title":"Circulation"},{"key":"2628_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"3","key":"2628_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ccd.23306","volume":"80","author":"S-L Chen","year":"2012","unstructured":"Chen S-L, Xu T, Zhang J-J et al (2012) Angioscopy study from a large patient population comparing sirolimus-eluting stent with biodegradable versus durable polymer. Catheter Cardiovasc Interv 80(3):420\u2013428","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"2628_CR19","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","volume":"48","author":"DE Kandzari","year":"2006","unstructured":"Kandzari DE, Leon MB, Popma JJ et al (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48(12):2440\u20132447","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2628_CR20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R et al (2007) Clinical end points in coronary stent trials. Circulation 115(17):2344\u20132351","journal-title":"Circulation"},{"issue":"7","key":"2628_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4244\/EIJV5I7A146","volume":"5","author":"V Pascal","year":"2010","unstructured":"Pascal V, Donald EC, Roxana M et al (2010) Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. EuroIntervention 5(7):871\u2013874","journal-title":"EuroIntervention"},{"issue":"4","key":"2628_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3(4):285\u2013299","journal-title":"Res Synth Methods"},{"issue":"1","key":"2628_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, Brenner D, Arora P (2019) BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses. BMC Med Res Methodol 19(1):196","journal-title":"BMC Med Res Methodol"},{"key":"2628_CR24","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002","journal-title":"BMJ"},{"key":"2628_CR25","first-page":"110","volume":"99","author":"JA Sterne","year":"2005","unstructured":"Sterne JA, Egger M (2005) Regression methods to detect publication and other bias in meta-analysis. Publ Bias Meta-Anal 99:110","journal-title":"Publ Bias Meta-Anal"},{"key":"2628_CR26","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"issue":"1","key":"2628_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.114.013520","volume":"131","author":"C Kaiser","year":"2015","unstructured":"Kaiser C, Galatius S, Jeger R et al (2015) Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivit\u00e4ts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 131(1):74\u201381","journal-title":"Circulation"},{"issue":"3","key":"2628_CR28","doi-asserted-by":"publisher","first-page":"e003255","DOI":"10.1161\/JAHA.116.003255","volume":"5","author":"R Zbinden","year":"2016","unstructured":"Zbinden R, Piccolo R, Heg D et al (2016) Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial. J Am Heart Assoc 5(3):e003255","journal-title":"J Am Heart Assoc"},{"key":"2628_CR29","doi-asserted-by":"publisher","first-page":"k3793","DOI":"10.1136\/bmj.k3793","volume":"363","author":"E Kedhi","year":"2018","unstructured":"Kedhi E, Fabris E, van der Ent M et al (2018) Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 363:k3793","journal-title":"BMJ"},{"issue":"17","key":"2628_CR30","first-page":"1650","volume":"12","author":"RA Buiten","year":"2019","unstructured":"Buiten RA, Ploumen EH, Zocca P et al (2019) Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT. JACC: Cardiovasc Interv 12(17):1650\u20131660","journal-title":"JACC: Cardiovasc Interv"},{"issue":"24","key":"2628_CR31","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T et al (2019) Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 321(24):2414\u20132427","journal-title":"JAMA"},{"issue":"18","key":"2628_CR32","doi-asserted-by":"publisher","first-page":"e1518","DOI":"10.4244\/EIJ-D-19-00865","volume":"16","author":"X Kai","year":"2021","unstructured":"Kai X, Bo X, Changdong G et al (2021) Biodegradable polymer-coated versus durable polymer-coated sirolimus-eluting stents: the final 5-year outcomes of the I-LOVE-IT 2 trial. EuroIntervention 16(18):e1518\u2013e1526","journal-title":"EuroIntervention"},{"issue":"23","key":"2628_CR33","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A et al (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310(23):2510\u20132522","journal-title":"JAMA"},{"issue":"11","key":"2628_CR34","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","volume":"15","author":"G De Luca","year":"2019","unstructured":"De Luca G, Damen SA, Camaro C et al (2019) Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 15(11):e990\u2013e998","journal-title":"EuroIntervention"},{"issue":"9","key":"2628_CR35","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.3889\/oamjms.2019.345","volume":"7","author":"A-AY Fawzy","year":"2019","unstructured":"Fawzy A-AY, Kenawi MM, Aziz AAE, Moharam AN, Attia IM (2019) Comparison between the outcomes of using biodegradable-polymer drug-eluting stents and those of using durable-polymer drug-eluting stents in acute coronary syndrome patients undergoing percutaneous coronary intervention. Open Access Maced J Med Sci 7(9):1466\u20131470","journal-title":"Open Access Maced J Med Sci"},{"issue":"15","key":"2628_CR36","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH et al (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60(15):1340\u20131348","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2628_CR37","doi-asserted-by":"publisher","first-page":"e018366","DOI":"10.1161\/JAHA.120.018366","volume":"10","author":"KH Yun","year":"2021","unstructured":"Yun KH, Lee SY, Cho BR et al (2021) Safety of 3-month dual antiplatelet therapy after implantation of ultrathin sirolimus-eluting stents with biodegradable polymer (Orsiro): results from the SMART-CHOICE trial. J Am Heart Assoc 10(1):e018366","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"2628_CR38","first-page":"1438","volume":"9","author":"SJ Hong","year":"2016","unstructured":"Hong SJ, Shin DH, Kim JS et al (2016) 6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC: Cardiovasc Interv 9(14):1438\u20131446","journal-title":"JACC: Cardiovasc Interv"},{"issue":"7","key":"2628_CR39","doi-asserted-by":"publisher","first-page":"e019630","DOI":"10.1161\/JAHA.120.019630","volume":"10","author":"JY Cho","year":"2021","unstructured":"Cho JY, Lee S-Y, Yun KH et al (2021) Factors related to major bleeding after ticagrelor therapy: results from the TICO trial. J Am Heart Assoc 10(7):e019630\u2013e019630","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2628_CR40","first-page":"1215","volume":"10","author":"GJ Vlachojannis","year":"2017","unstructured":"Vlachojannis GJ, Smits PC, Hofma SH et al (2017) Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent). JACC: Cardiovasc Interv 10(12):1215\u20131221","journal-title":"JACC: Cardiovasc Interv"},{"issue":"10151","key":"2628_CR41","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392(10151):940\u2013949","journal-title":"Lancet"},{"issue":"23","key":"2628_CR42","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials. Circulation 123(23):2736\u20132747","journal-title":"Circulation"},{"issue":"10","key":"2628_CR43","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1056\/NEJM198903093201002","volume":"320","author":"Group TTS","year":"1989","unstructured":"Group TTS (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 320(10):618\u2013627","journal-title":"N Engl J Med"},{"issue":"6","key":"2628_CR44","first-page":"654","volume":"4","author":"R Mehran","year":"2011","unstructured":"Mehran R, Pocock S, Nikolsky E et al (2011) Impact of bleeding on mortality after percutaneous coronary intervention. JACC: Cardiovasc Interv 4(6):654\u2013664","journal-title":"JACC: Cardiovasc Interv"},{"issue":"10","key":"2628_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"TG Investigators","year":"1993","unstructured":"Investigators TG (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329(10):673\u2013682","journal-title":"N Engl J Med"},{"issue":"10","key":"2628_CR46","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA et al (2016) 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of st-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134(10):e123\u2013e155","journal-title":"Circulation"},{"issue":"24","key":"2628_CR47","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"J-Y Hahn","year":"2019","unstructured":"Hahn J-Y, Song YB, Oh J-H et al (2019) Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 321(24):2428\u20132437","journal-title":"JAMA"},{"issue":"21","key":"2628_CR48","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK et al (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381(21):2032\u20132042","journal-title":"N Engl J Med"},{"issue":"6","key":"2628_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10557-018-6823-9","volume":"32","author":"P Zocca","year":"2018","unstructured":"Zocca P, Kok MM, van der Heijden LC et al (2018) High bleeding risk patients treated with very thin-strut biodegradable polymer or thin-strut durable polymer drug-eluting stents in the BIO-RESORT trial. Cardiovasc Drugs Ther 32(6):567\u2013576","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"2628_CR50","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/CIRCULATIONAHA.118.038065","volume":"139","author":"S Kufner","year":"2019","unstructured":"Kufner S, Joner M, Thannheimer A et al (2019) Ten-year clinical outcomes from a trial of three limus-eluting stents with different Polymer coatings in patients with coronary artery disease. Circulation 139(3):325\u2013333","journal-title":"Circulation"},{"issue":"11","key":"2628_CR51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","volume":"143","author":"H-S Kim","year":"2021","unstructured":"Kim H-S, Kang J, Hwang D et al (2021) Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome. Circulation 143(11):1081\u20131091","journal-title":"Circulation"},{"issue":"13","key":"2628_CR52","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ et al (2011) Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123(13):1400\u20131409","journal-title":"Circulation"},{"issue":"4","key":"2628_CR53","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.21037\/jtd.2017.03.134","volume":"9","author":"NG Kounis","year":"2017","unstructured":"Kounis NG, Koniari I, Roumeliotis A et al (2017) Thrombotic responses to coronary stents, bioresorbable scaffolds and the Kounis hypersensitivity-associated acute thrombotic syndrome. J Thorac Dis 9(4):1155\u20131164","journal-title":"J Thorac Dis"},{"issue":"4","key":"2628_CR54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2005.09.060","volume":"47","author":"SV Rao","year":"2006","unstructured":"Rao SV, O\u2019Grady K, Pieper KS et al (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47(4):809\u2013816","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2628_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/heart.83.3.338","volume":"83","author":"DM Whelan","year":"2000","unstructured":"Whelan DM, van der Giessen WJ, Krabbendam SC et al (2000) Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 83(3):338\u2013345","journal-title":"Heart"},{"issue":"7","key":"2628_CR56","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1161\/01.CIR.94.7.1690","volume":"94","author":"WJvd Giessen","year":"1996","unstructured":"Giessen WJvd, Lincoff AM, Schwartz RS et al (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94(7):1690\u20131697","journal-title":"Circulation"},{"issue":"4","key":"2628_CR57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","volume":"63","author":"T Palmerini","year":"2014","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D et al (2014) Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 63(4):299\u2013307","journal-title":"J Am Coll Cardiol"},{"key":"2628_CR58","doi-asserted-by":"publisher","first-page":"f6625","DOI":"10.1136\/bmj.f6625","volume":"347","author":"S Bangalore","year":"2013","unstructured":"Bangalore S, Toklu B, Amoroso N et al (2013) Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 347:f6625","journal-title":"BMJ"},{"issue":"4","key":"2628_CR59","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"D Giacoppo","year":"2020","unstructured":"Giacoppo D, Matsuda Y, Fovino LN et al (2020) Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 42(4):308\u2013319","journal-title":"Eur Heart J"},{"issue":"2","key":"2628_CR60","first-page":"86","volume":"7","author":"S Benenati","year":"2020","unstructured":"Benenati S, Galli M, De Marzo V et al (2020) Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J 7(2):86\u201393","journal-title":"Eur Heart J"},{"key":"2628_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa127","author":"S Benenati","year":"2020","unstructured":"Benenati S, Crimi G, Canale C et al (2020) Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. Eur Heart J. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa127","journal-title":"Eur Heart J"},{"issue":"3","key":"2628_CR62","first-page":"196","volume":"7","author":"M Bianco","year":"2020","unstructured":"Bianco M, Careggio A, Destefanis P et al (2020) P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J 7(3):196\u2013205","journal-title":"Eur Heart J"},{"issue":"2","key":"2628_CR63","first-page":"e001441","volume":"8","author":"S Windecker","year":"2015","unstructured":"Windecker S, Haude M, Neumann F-J et al (2015) Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent. Circulation 8(2):e001441","journal-title":"Circulation"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02628-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02628-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02628-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T05:22:55Z","timestamp":1649395375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02628-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2628"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02628-8","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"27 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}